New Evidence: PREVENA™ Incision Management System Granted New FDA Indication to Aid in the Reduction of SSIs and Seromas

By 3M+KCI FEATURING Ronald Silverman
October 10, 2019

Please listen in as Ron Silverman, MD discusses how PREVENA™ Incision Management System has been newly indicated by the FDA to aid in the reduction of seromas and to aid high-risk patients by reducing the incidence of SSI’s in Class I and Class II wounds.

- Explore why PREVENA™ Therapy is the FIRST and ONLY negative pressure wound therapy device to have these clinical outcomes included in its indication statement
- Understand the impact of SSIs for high-risk patients
- Overview of meta-analyses of two different negative pressure therapy systems in closed incision management
Login to view comments. Click here to Login